Mononucleosis infecciosa

1 Hurt C, Tammaro D. Diagnostic evaluation of mononucleosis-like illnesses. Am J Med 2007;120:911 e1-8.
2 Thorley-Lawson DA, Miyashita EM, Khan G. Epstein-Barr virus and the B cell: that’s all it takes. Trends Microbiol 1996;4:204-8.
3 Schuster V, Kreth HW. Epstein-Barr virus infection and associated diseases in children. I. Pathogenesis, epidemiology and clinical aspects. Eur J Pediatr 1992;151:718-25.
4 Tattevin P, Le Tulzo Y, Minjolle S, et al. Increasing incidence of severe Epstein-Barr virus-related infectious mononucleosis: surveillance study. J Clin Microbiol 2006;44:1873-4.
5 Macsween KF, Crawford DH. Epstein-Barr virus-recent advances. Lancet Infect Dis 2003;3:131-40.
6 Hoagland RJ. Infectious mononucleosis. Prim Care 1975;2:295-307.
7 Kofteridis DP, Koulentaki M, Valachis A, et al. Epstein Barr virus hepatitis. Eur J Intern Med 2011;22:73-6.
8 Lennon P, O’Neill JP, Fenton JE, et al. Challenging the use of the lymphocyte to white cell count ratio in the diagnosis of infectious mononucleosis by analysis of a large cohort
of Monospot test results. Clin Otolaryngol 2010;35:397-401.
9 Centers for Disease Control and Prevention. Epstein-Barr virus and infectious
mononucleosis, laboratory testing. 2014. www.cdc.gov/epstein-barr/laboratory-testing.html.
10 Vouloumanou EK, Rafailidis PI, Falagas ME. Current diagnosis and management of
infectious mononucleosis. Curr Opin Haematol 2012;19:14-20.
11 Torre D, Tambini R. Acyclovir for treatment of infectious mononucleosis: a meta-analysis. Scand J Infect Dis 1999;31:543-7.
12 Lennon P, O’Neill JP, Fenton JE. Effect of metronidazole versus standard care on length of stay of patients admitted with severe infectious mononucleosis: a randomized controlled trial. Clin Microbiol Infect 2014;20:O450-2.
13 Candy B, Hotopf M. Steroids for symptom control in infectious mononucleosis. Cochrane Database Syst Rev 2006;3:CD004402.
14 Hayward G, Thompson MJ, Perera R, et al. Corticosteroids as standalone or add-on treatment for sore throat. Cochrane Database Syst Rev 2012;10:CD008268.
15 Petersen I, Thomas JM, Hamilton WT, et al. Risk and predictors of fatigue after infectious mononucleosis in a large primary-care cohort. Q J Med 2006;99:49-55.
16 Chronic fatigue syndrome: going viral? Lancet 2010;376:930.
17 Hosey RG, Kriss V, Uhl TL, et al. Ultrasonographic evaluation of splenic enlargement in
athletes with acute infectious mononucleosis. Br J Sports Med 2008;42:974-7.
18 Becker JA, Smith JA. Return to play after infectious mononucleosis. Sports Health 2014;6:232-8.
19 Thacker EL, Mirzaei F, Ascherio A. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann Neurol 2006;59:499-503.
20 Cohen JI, Fauci AS, Varmus H, et al. Epstein-Barr virus: an important vaccine target for cancer prevention. Sci Transl Med 2011;3:107fs7.
21 Hjalgrim H, Smedby KE, Rostgaard K, et al. Infectious mononucleosis, childhood social environment, and risk of Hodgkin lymphoma. Cancer Res 2007;67:2382-8.
22 Goldacre MJ, Wotton CJ, Yeates DG. Associations between infectious mononucleosis and cancer: record-linkage studies. Epidemiol Infect 2009;137:672-80.